Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Saved in:
Bibliographic Details
Title: Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.
Authors: Vodička P; First Department of Medicine, First Faculty of Medicine Charles University and General Hospital, Prague, Czech Republic.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., El-Galaly TC; Departments of Hematology, Clinical Epidemiology, and Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Procházka V; Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic., Flowers CR; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Villa D; Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada., Dietrich CE; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Jakobsen LH; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark., Ghesquières H; Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France., Clausen MR; Department of Medicine, Vejle Hospital, Vejle, Denmark., Kridel R; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Cheah CY; Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia.; Department of Internal Medicine, The University of Western Australia Medical School, Perth, Australia., Hawkes EA; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia., Wahlin B; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.; Institution for Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden., Gandhi MK; Translational Research Institute, Mater Research Institute University of Queensland, Brisbane, QLD, Australia., Larson MC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., Cahn EJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., Friedberg JW; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Martin P; Department of Medicine, Weill Cornell Medicine, New York, NY., Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Cohen JB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Habermann TM; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Casulo C; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Wang Y; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., de Nully Brown P; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Mou E; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA., Belada D; Fourth Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic., Janíková A; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Móciková H; Department of Hematology, Fakultni Nemocnice Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic., Burack R; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY., Lossos IS; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Kahl BS; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Smedby KE; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Sehn LH; Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada., Trněný M; First Department of Medicine, First Faculty of Medicine Charles University and General Hospital, Prague, Czech Republic., Cerhan JR; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., Maurer MJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Source: Blood [Blood] 2026 Jun 25; Vol. 147 (26), pp. 3248-3252.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2026033090